Proton radiation therapy in the treatment of solid tumours
Authors:
J. Kubeš 1,2; V. Vondráček 1; J. Abrahámová 1,3
Authors place of work:
Proton Therapy Center Czech s. r. o., Praha, Primář: MUDr. Jiří Kubeš, PhD.
1; Onkologická klinika 2. LF UK a FN Motol, Praha, Přednostka: doc. MUDr. Jana Prausová, PhD., MBA
2; Komplexní onkologické centrum Nemocnice Na Bulovce ve spolupráci se Všeobecnou fakultní nemocnicí v Praze a Thomayerovou nemocnicí, Vedoucí: prof. MUDr. Jitka Abrahámová, DrSc.
3
Published in the journal:
Prakt. Lék. 2019; 99(1): 3-10
Category:
Various Specialization
Summary
Proton radiotherapy is a form of ionizing radiation treatment using accelerated protons. The basic physical property of proton radiation is that they deliver most of their energy at the end of their path in the tissue, which is final and its depth is given by the initial energy of the protons. This leads to a dose distribution of radiation, which, compared to modern photon radiation Therapy, places less burden on healthy tissues, especially in the middle and low dose range. The first irradiation of the proton took place in 1954 and the method is technologically mature. Indications are discussed – we describe indications most common in proton centres as well as published results.
Keywords:
proton radiotherapy – pencil beam scanning – solid tumours
Zdroje
1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355(15): 1572–1582.
2. Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013; 107(3): 267–273.
3. Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013; 97(7): 804–811.
4. Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol) 2016; 28(8): e17–27.
5. Combs SE, Kessel K, Habermehl D, et al. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol 2013; 52(7): 1504–1509.
6. Dennis ER, Bussiere MR, Niemierko A, et al. Comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat 2013; 12(1): 1–9.
7. Arvold, ND, Niemierko A, Broussard GP, et al. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Int J Radiat Oncol Biol Phys 2012; 83(4): e495–500.
8. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999; 175(Suppl 2): 57–63.
9. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 2009; 75(4): 1111–1118.
10. Harrabi SB, Bougatf N, Mohr A, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol 2016; 192(11): 759–769.
11. Karunamuni R, Bartsch H, White NS, et al. Dose-dependent cortical thinning after partial brain irradiation in high-grade glioma. Int J Radiat Oncol Biol Phys 2016; 94(2): 297–304.
12. Adeberg S, Harrabi SB, Bougatf N, et al. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma: A dosimetric comparison. Strahlenther Onkol 2016; 192(11): 770–779.
13. Adeberg S, Bernhardt D, Harrabi SB, et al. Sequential proton boost after standard chemoradiation for high-grade glioma. Radiother Oncol 2017; 125(2): 266–272.
14. Mizumoto M, Okumura T, Ishikawa E, et al. Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. Strahlenther Onkol 2013; 189(8): 656–663.
15. Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys 2006; 64(2): 425–434.
16. Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013; 86(2): 277–284.
17. McDonald MW, Plankenhorn DA, McMullen KP, et al. Proton therapy for atypical meningiomas. J Neurooncol 2015; 123(1): 123–128.
18. Merchant TE, Schreiber JE, Wu S, et al. Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma. Int J Radiat Oncol Biol Phys 2014; 90(3): 554–561.
19. Greenberger, BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 2014; 89(5): 1060–1068.
20. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol 2014; 15(9): 1027–1038.
21. Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 2014; 113(3): 364–370.
22. McDowell LJ, Ringash J, Xu W, et al. A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. Radiother Oncol 2018; pii: S0167-8140(18)33495-9.
23. Wu LR, Liu YT, Jiang N. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center. Oral Oncol 2017; 69: 26–32.
24. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol 2016; 120(1): 48–55.
25. Chuong MD, Bhooshan N, Allen PK, et al. A multi-institutional analysis of acute toxicity after neoadjuvant chemoradiation using photons or protons in trimodality esophageal cancer patients. Int J Radiat Oncol Biol Phys 2015; 93(3 Suppl): S220.
26. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290(21): 2831–2837.
27. Cellai E, Magrini SM, Masala G, et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin‘s disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 2001; 49(5): 1327–1337.
28. Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys 2017; 99(4): 825–842.
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hodgkin lymphoma. Version 3.2018 [online]. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf [cit. 2018-11-02].
30. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: The international lymphoma radiation oncology group (ILROG) guidelines. Blood 2018; 32(16): 1635–1646.
31. Tseng YD, Hoppe BS, Miller D, et al. Rates of toxicity and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma. Int J Radiat Oncol Biol Phys 2017; 99(2 Suppl): S62–S63.
32. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba. Int J Radiat Oncol Biol Phys 2010; 78(2): 467–471.
33. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011; 117(13): 3004–3013.
34. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 2018; 36(18): 1813–1822.
35. Jethwa KR, Tryggestad EJ, Whitaker TJ, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol 2018; 3(3): 314–321.
36. Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol 2012; 103(1): 25–31.
37. Kim TH, Lee WJ, Woo SM, et al. Effectiveness and safety of simultaneous integrated boost-proton beam therapy for localized pancreatic cancer. Technol Cancer Res Treat 2018; 17: 533033818783879.
38. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009; 115: 5499–5506.
39. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011; 117(13): 3053–3059.
40. Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2015; 114: 289–295.
41. Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 2016; 95(1): 477–482.
42. Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol 2014; 110(1): 165–171.
43. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 4.2018 [online]. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [cit. 2018-11-02].
44. Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2016; 95(1): 422–434.
45. Takagi M, Demizu Y, Terashima K, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med 2017; 6(10): 2234–2243.
46. Iwata H, Ishikawa H, Takagi M, et al. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med 2018; 7(3): 677–689.
47. Ho CK, Bryant CM, Mendenhall NP, et al. Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. Acta Oncol 2018; 57(5): 582–588.
48. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368(11): 987–998.
49. Cheng YJ, Nie XY, Ji CC. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc 2017; 6(5): pii: e005633.
50. Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 2012; 30(4): 380–386.
51. Particle Therapy Co-Operative Group. Particle therapy centers [online]. Dostupné z: www.ptcog.ch [cit. 2018-11-02].
52. Health Council of the Netherlands. Proton radiotherapy. Horizon scanning report.
The Hague: Health Council of the Netherlands, 2009; publication No. 2009/17E.
Štítky
General practitioner for children and adolescents General practitioner for adults Haematology Surgery Clinical oncology ENT (Otorhinolaryngology) UrologyČlánok vyšiel v časopise
General Practitioner
2019 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Chronic stress as a risk factor for the incidence and progression of cancer?
- Proton radiation therapy in the treatment of solid tumours
- Personal dignity of a patient with multiple sclerosis: interpretative phenomenological analysis
- Health literacy of the Romany minority in the Czech Republic